Novasep moves eravacycline API to commercial-scale production

Novasep has won a contract to make commercial supplies of the API eravacycline, a next-generation infection fighter.

French CDMO Novasep, which has been making clinical supplies for a new-generation antibiotic being developed by U.S.-based Tetraphase Pharmaceuticals, will now start production for a potential commercial launch next year.

Novasep said it will continue to manufacture eravacycline at its facility in Chasse-sur-Rhône, France, where it has produced the clinical supply of the API since 2014. Eravacycline is a novel, fully synthetic tetracycline antibiotic under development for the treatment of life-threatening infections, including those caused by multidrug-resistant Gram-negative bacteria.

In its third-quarter report last month, Watertown, Massachusetts-based Tetraphase said that it had completed a phase 3 clinical trial which it will use along with data from an earlier trial for its NDA to treat complicated intra-abdominal infections and complicated urinary tract infections. It said it expects to file the NDA in the first quarter of 2018.


Simplify and Accelerate Drug R&D With the MarkLogic Data Hub Service for Pharma R&D

Researchers are often unable to access the information they need. And, even when data does get consolidated, researchers find it difficult to sift through it all and make sense of it in order to confidently draw the right conclusions and share the right results. Discover how to quickly and easily find, synthesize, and share information—accelerating and improving R&D.

RELATED: Tetraphase shares tank as FDA demands new antibiotic PhIII trial

The FDA told Tetraphase in May 2016 that it would need further clinical data before it could consider approving eravacycline. Tetraphase has also submitted a Marketing Authorisation Application in Europe for the same use of eravacycline.  

Suggested Articles

Sanofi, which has moved purposefully into high technologies to get more from its manufacturing, will lean even more on that strategy to save costs.

Just months after a C-suite shakeup at Amneal, the generics company has struck a $220 million deal for AvKare, known on the street as R&S Northeast. 

Fujifilm has completed the first manufacturing facility in Japan to make drug-delivering liposomes to use for cancer fighting drugs it is developing.